Ellington Management Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ellington Management Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-8,500	Closed	-$925K	–	55
2020 Q1	$925K	Buy	+8,500	New	+$981K	0.22%	122
2019 Q2	–	Sell	-4,800	Closed	-$449K	–	565
2019 Q1	$449K	Buy	4,800 +700	+17%	+$58.5K	0.08%	256
2018 Q4	$299K	Buy	+4,100	New	+$315K	0.09%	225
2017 Q3	–	Sell	-5,900	Closed	-$471K	–	613
2017 Q2	$471K	Buy	+5,900	New	+$377K	0.07%	258
2014 Q2	–	Sell	-9,300	Closed	-$624K	–	439
2014 Q1	$624K	Buy	+9,300	New	+$720K	0.18%	158

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Ellington Management Group's ALNY Position: Q2 2020 in Review

Ellington Management Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2020, closing a stake of 8,500 shares — an estimated $925K sold.

Ellington Management Group first reported a position in ALNY in Q1 2014 and held it in 5 quarters. The position peaked at $925K in Q1 2020. 375 funds tracked by Wall St. Rank hold ALNY as of Q2 2020.

Ellington Management Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Ellington Management Group sold 8,500 Alnylam Pharmaceuticals shares in Q2 2020, an estimated $925K.
Ellington Management Group first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Ellington Management Group's Alnylam Pharmaceuticals position peaked at $925K in Q1 2020.
375 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.